Review
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Oct 27, 2021; 13(10): 1234-1268
Published online Oct 27, 2021. doi: 10.4254/wjh.v13.i10.1234
In the era of rapid mRNA-based vaccines: Why is there no effective hepatitis C virus vaccine yet?
Natalia Echeverría, Victoria Comas, Fabián Aldunate, Paula Perbolianachis, Pilar Moreno, Juan Cristina
Natalia Echeverría, Fabián Aldunate, Paula Perbolianachis, Pilar Moreno, Juan Cristina, Laboratorio de Virología Molecular, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Montevideo 11400, Uruguay
Natalia Echeverría, Fabián Aldunate, Paula Perbolianachis, Pilar Moreno, Laboratorio de Evolución Experimental de Virus, Institut Pasteur, Montevideo 11400, Uruguay
Victoria Comas, Departamento de Desarrollo Biotecnológico, Instituto de Higiene, Facultad de Medicina, Universidad de la República, Montevideo 11600, Uruguay
Author contributions: Echeverría N contributed to bibliographical revision, article conception, design and drafting, and figure design; Comas V made contributions to article drafting; Perbolianachis P and Aldunate F contributed to bibliographical revision and made revisions related to draft and content; Moreno P and Cristina J made substantial contributions to conception and design, article drafting and revision of intellectual content; all authors contributed to final approval of the version to be published.
Supported by Programa de Desarrollo de las Ciencias Básicas (PEDECIBA); Comisión Académica de Posgrados, Universidad de la República Uruguay (UdelaR); and Comisión Sectorial de Investigación Científica (CSIC, I+D Project ID288).
Conflict-of-interest statement: Dr. Echeverría reports grants from Comisión Sectorial de Investigación Científica (CSIC) and from Comisión Académica de Posgrados (CAP). Dr Echeverría, Dr. Cristina and Dr. Moreno report personal research funding from PEDECIBA. MSc Comas, MSc Aldunate and MSc Perbolianachis declare no conflict of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Juan Cristina, PhD, Full Professor, Laboratorio de Virología Molecular, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Mataojo 2055, Montevideo 11400, Uruguay. cristina@cin.edu.uy
Received: March 4, 2021
Peer-review started: March 4, 2021
First decision: May 2, 2021
Revised: May 14, 2021
Accepted: September 10, 2021
Article in press: September 10, 2021
Published online: October 27, 2021
Core Tip

Core Tip: Hepatitis C virus (HCV) remains a global health burden despite the successful introduction of direct-acting antiviral therapies. In order to achieve global control of HCV epidemic a vaccine is necessary. Its development has faced many hurdles, reason why it is still elusive. Herein, we describe all the challenges during HCV vaccine research, focusing on HCV immunology and emphasizing on current vaccine candidates, particularly nucleic acid-based as well as recombinant vector-based vaccines. We also highlight the impact of severe acute respiratory syndrome coronavirus-2 vaccine race on the renewed interest on HCV vaccine production. Finally, we present ideas on live-attenuated vaccine approaches against HCV.